Tweet Immune response to EBV may control what the outcome is in relation to the infection, whether it is cancer or autoimmunity. I am sorry I don’t have the time or inclination to break this down further. Kamitaki N, Tang D, McCarroll SA, Loh PR. The DNA virome varies with human genes and environments. Nature….
EMA grants PRIME status to new optic neuritis therapy privosegtor
The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can lead to lasting vision problems. While also associated with…
Personalised Medicine is the Buzz Word…but where is it in MS?
Tweet Personalized medicine has been a mantra for some years but in many cases this is just a pipe-dream. Personalization means screening to do selection and this equates to cost. It also takes time. Any screening is typically borne by the manufacturer. e.g., who pays for the genomic testing for siponimod as peoples genetics determine…
Learning to be cared for
When I look back on my life of nearly 60 years, I am struck by how much of that life has been focused on the care of others around me. The people I’ve cared for are a varied group ranging from the teams that reported to me during my 30+ year career in advertising to…
New model of nerve fibers could speed path for MS treatments
A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to be less effective in these softer…
Quantum Biopharma seeks FDA clearance to test Lucid-MS in patients
Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in the brain. The Investigational New Drug (IND) application…
Early and effectively to limit future Progression
Tweet Progression independent of relapse (clinical & Imaging) drives disability and is the basis for progression of disability. Natalizumab has its main action outside of the brain so any influence on progression would be due to stopping the consequences of damaging immune attack from entering into the CNS. Once sufficient damage is accumulated then a…
I keep telling you this.
Tweet We are over dosing anti-CD20 therapy in most people. I know you are fed up with these posts but I need to make comments on this so I can say “I told you so a decade ago”…Someone may pipe up and say they said this way before that…yet we are doing trials on this…
MS Canada invites cyclists to join summer fundraising rides
MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money for research, advocacy, and support services. This year’s…